Benign prostatic hyperplasia (BPH) is one of those “bread-and-butter” male reproductive topics that shows up everywhere on Step 1 and Step 2—often disguised as a urinary complaint in an older man. The key is to connect anatomy (where the prostate grows), physiology (why it grows), and symptoms (how it obstructs), then know the classic meds and their side effects cold.
What is BPH?
Benign prostatic hyperplasia (BPH) is a nonmalignant proliferation of prostatic glands and stroma that leads to enlargement of the prostate, most prominently in the periurethral/transitional zone, causing lower urinary tract symptoms (LUTS) due to urethral compression.
First Aid cross-reference
- FA Step 1 (Reproductive – Prostate pathology): BPH = hyperplasia in the transitional zone, DHT-driven, causes urinary symptoms, ↑ PSA may occur but not diagnostic of cancer.
Why it matters for boards (the core “big picture”)
BPH is a mechanical + dynamic obstruction problem:
- Mechanical (static) component: the gland is bigger → narrows the prostatic urethra
- Dynamic component: α-mediated smooth muscle tone in prostate/bladder neck increases resistance
That’s why two drug classes make sense:
- α blockers improve flow quickly
- 5α-reductase inhibitors shrink prostate slowly by reducing DHT
Pathophysiology: the DHT story (high yield)
Key hormone conversion
Testosterone is converted to dihydrotestosterone (DHT) by 5α-reductase (especially in prostate stromal cells).
- DHT binds androgen receptors → increases growth factors → proliferation of prostatic glands and stroma
- With aging, the prostate becomes more sensitive to androgens and local growth signaling
Board-relevant pearl
- BPH is driven by DHT, not just testosterone → explains why finasteride/dutasteride work.
Anatomy that Step questions love: zones of the prostate
| Prostate zone | Classic association | High-yield detail |
|---|---|---|
| Transitional (periurethral) | BPH | Compresses urethra → LUTS |
| Peripheral (posterior) | Prostate adenocarcinoma | Palpable on DRE; “hard, irregular nodule” |
First Aid cross-reference
- BPH: transitional zone
- Cancer: peripheral zone
Clinical presentation (LUTS): recognize the pattern
BPH symptoms typically develop gradually in older men.
Obstructive (voiding) symptoms
- Hesitancy
- Weak stream
- Intermittency (“start-stop” stream)
- Straining
- Incomplete emptying
- Postvoid dribbling
Irritative (storage) symptoms
- Frequency
- Urgency
- Nocturia
Complications (testable)
- Acute urinary retention (often precipitated by anticholinergics, sympathomimetics, anesthesia)
- Recurrent UTIs
- Bladder stones
- Hydronephrosis → postrenal azotemia in severe cases
- Hematuria (from congested prostatic vessels)
Diagnosis: what you do (and don’t) need
BPH is usually a clinical diagnosis supported by targeted testing.
History tools
- IPSS/AUA-SI symptom score (common in clinical vignettes)
Physical exam
- DRE: typically enlarged, smooth, rubbery, symmetric prostate
- Compare with cancer: hard, nodular, asymmetric
Labs
- Urinalysis: evaluate for infection/hematuria
- PSA: may be mildly elevated in BPH due to increased glandular tissue
- PSA is not specific: increases in BPH, prostatitis, cancer
- If they mention tender boggy prostate + fever, think prostatitis, not BPH
Imaging / functional testing (Step 2 style)
- Postvoid residual (PVR): often increased
- Uroflowmetry: decreased peak flow
- Renal ultrasound if concern for obstruction/hydronephrosis
Differential diagnosis: quick Step-ready separation
| Condition | Clues | Prostate exam |
|---|---|---|
| BPH | Gradual LUTS, older age, nocturia/hesitancy | Smooth, enlarged |
| Prostate cancer | Often asymptomatic early; later bone pain, weight loss | Hard, nodular |
| Acute bacterial prostatitis | Fever, chills, dysuria, pelvic/perineal pain | Tender, boggy (avoid vigorous massage) |
| Urethral stricture | History of instrumentation/STI/trauma, weak stream | Prostate may be normal |
| Neurogenic bladder | Diabetes, spinal cord disease, MS | Variable |
Treatment: stepwise and mechanism-driven
1) Watchful waiting (mild symptoms)
- Lifestyle:
- Limit evening fluids
- Reduce caffeine/alcohol
- Timed voiding
- Monitor symptoms and complications
2) First-line meds (moderate to severe symptoms)
α blockers (fast symptom relief)
Examples:
- Tamsulosin (more α selective → fewer systemic BP effects)
- Alfuzosin
- Doxazosin, terazosin (less selective → more orthostasis)
Mechanism:
- Relax smooth muscle in prostate and bladder neck → improved urine flow
High-yield adverse effects:
- Orthostatic hypotension (especially nonselective agents)
- Dizziness
- Ejaculatory dysfunction
- Intraoperative floppy iris syndrome (classically with tamsulosin)
5α-reductase inhibitors (shrink prostate; slower onset)
Examples:
- Finasteride, dutasteride
Mechanism:
- Inhibit conversion of testosterone → DHT → decreased prostate volume over months
High-yield uses/pearls:
- Best when prostate is enlarged (large gland, higher PSA from benign tissue)
- Can lower risk of urinary retention and need for surgery
High-yield adverse effects:
- Decreased libido
- Erectile dysfunction
- Ejaculatory dysfunction
- Gynecomastia
- Decreased PSA (important for screening interpretation)
PSA nuance: 5α-reductase inhibitors can reduce PSA; in practice, clinicians adjust interpretation. For Step purposes: finasteride lowers PSA.
Combination therapy (common Step 2 concept)
- α blocker + 5α-reductase inhibitor for significant symptoms + large prostate
3) When meds fail or complications occur
Indications to escalate:
- Refractory symptoms
- Recurrent urinary retention
- Recurrent UTIs
- Bladder stones
- Hydronephrosis/renal dysfunction
Procedures:
- TURP (transurethral resection of the prostate): classic definitive therapy
- Minimally invasive options: laser therapies, prostatic urethral lift, etc. (less Step 1, occasional Step 2)
High-yield associations and classic vignettes
The classic presentation
- 68-year-old man with nocturia, hesitancy, weak stream, incomplete emptying
- DRE: smoothly enlarged prostate
- PVR increased
Medication trigger for acute urinary retention
They love to ask: “What precipitated this?”
- Anticholinergics (e.g., first-gen antihistamines, TCAs) → decrease detrusor contraction
- Sympathomimetics (e.g., decongestants like pseudoephedrine) → increase sphincter tone
- Opioids / anesthesia post-op
“BPH vs cancer” one-liners
- BPH: transitional zone, obstructive symptoms, smooth enlargement
- Cancer: peripheral zone, hard nodule, may metastasize to bone (osteoblastic lesions)
Board-style rapid review (what to memorize)
Must-know bullets
- BPH occurs in the transitional zone → compresses urethra
- Driven by DHT (5α-reductase)
- Symptoms: hesitancy, weak stream, nocturia, incomplete emptying
- DRE: smooth, enlarged, symmetric
- α blockers = quick relief; orthostatic hypotension, floppy iris
- Finasteride/dutasteride = slow shrinkage; sexual side effects, ↓ PSA
- Complications: UTI, retention, hydronephrosis
Quick table: drugs at a glance
| Drug class | Examples | Onset | Best for | Major adverse effects |
|---|---|---|---|---|
| α blockers | Tamsulosin, alfuzosin, doxazosin, terazosin | Days | Rapid symptom relief | Orthostasis (esp nonselective), dizziness, ejaculatory dysfunction, floppy iris |
| 5α-reductase inhibitors | Finasteride, dutasteride | Months | Large prostate, prevention of progression | Sexual dysfunction, gynecomastia, ↓ PSA |
First Aid tie-ins (how it’s tested)
When you see “older man + LUTS,” Step expects you to quickly map:
- Zone: transitional → BPH
- Hormone: DHT → 5α-reductase
- Treatment: α blocker for symptoms; finasteride/dutasteride for size/progression
- DRE: smooth vs nodular distinction
If you can say those four things confidently, you’ll pick up most BPH points across both Step 1 and Step 2.